Edwards Lifesciences Corporation (NYSE: EW), today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450 commercial centers around the U.S. show consistently positive patient outcomes....
WSJ’s John Carreyrou says Theranos is a ‘cautionary tale’ for the health-tech industry via @Recode | https://t.co/NpdiPEpMqc pic.twitter.com/kdHiAQSzWt
— medtech[y] (@medtechy) May 22, 2018
Doctor who made music videos in operating room facing several malpractice suits https://t.co/deJtdeLPLW pic.twitter.com/epFsWz87JR
— medtech[y] (@medtechy) May 21, 2018
Yesterday, during the American Urological Association Annual Meeting (AUA), PROCEPT Biorobotics announced early data from the global Phase III WATER II (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) Study showing the achievement of primary safety and efficacy endpoints for Aquablation in the treatment of benign prostatic hyperplasia (BPH). ...
On CNBC's "Power Lunch," a Wall Street analyst stated that Amgen's recently approved migraine drug, Aimovig, could become a $2 billion business in the next five years. That revenue would equate to a 10 percent increase to Amgen's revenue as the drug provides a huge unmet need for adults who deal with migraines. ...
Amgen's new migraine drug will cost 30 percent less than Wall Street expected via @statnews $AMGN https://t.co/mw5s8bXdjN pic.twitter.com/hdnOZ52cMg
— medtech[y] (@medtechy) May 18, 2018
My latest deep dive on the struggles with the Amazon, JPM, Berkshire Hathaway CEO search, and who's emerged as a top name in recent weeks (hint: it's a health-tech CEO) https://t.co/NY6iZ2OfRI tip @Techmeme
— Christina Farr (@chrissyfarr) May 16, 2018
The following slide presentation was published by MiMedx in conjunction with the Bank of America Merrill Lynch 2018 Healthcare Conference. ...
Allergan is taking advantage of the popularity of CoolSculpting, the procedure they acquired from ZELTIQ, by launching a DTC marketing campaign. CoolSculpting revenue has continued strong growth in recent quarters and helped offset declines in other Allergan product categories....
Novartis sacrifices its top attorney in an attempt to quell clamor over $1.2M in Cohen payments — while ex-CEO Jimenez struggles to explain via @endpts $NVS https://t.co/yu5bz4BFZf pic.twitter.com/Y5l6GaZow4
— medtech[y] (@medtechy) May 17, 2018